Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia

Daniëlla M. Oosterveer; Jorie Versmissen; Arend F.L. Schinkel; Janneke G. Langendonk; Monique Mulder; Eric J.G. Sijbrands

doi:10.2217/clp.10.9

Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia

Daniëlla M. Oosterveer, Jorie Versmissen^*, Arend F.L. Schinkel, Janneke G. Langendonk, Monique Mulder, Eric J.G. Sijbrands

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

7 Citations (Scopus)

4 Downloads (Pure)

Abstract

Patients with familial hypercholesterolemia (FH) have high levels of LDL-C, owing to defective uptake of these particles by LDL receptors in the liver. Consequently, FH patients have a high risk of cardiovascular disease (CVD). However, among these patients, there is marked variance in age of onset of CVD and a proportion of untreated patients do not develop CVD at all. Statin treatment can greatly reduce risk, and since it is not yet possible to precisely predict which FH patients will develop CVD, all patients initiate treatment once the diagnosis has been made. The purpose of this article is to provide an update of clinical and genetic risk factors influencing CVD risk in FH patients, and to discuss future lines of research that could uncover improved methods of treatment for heterozygous FH patients.

Original language	English
Pages (from-to)	189-197
Number of pages	9
Journal	Clinical Lipidology
Volume	5
Issue number	2
DOIs	https://doi.org/10.2217/clp.10.9
Publication status	Published - Apr 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/clp.10.9Licence: CC BY

Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemiaFinal published version, 593 KBLicence: CC BY

Cite this

@article{66f4f06b07e74614bf5b539b1bdf790a,

title = "Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia",

abstract = "Patients with familial hypercholesterolemia (FH) have high levels of LDL-C, owing to defective uptake of these particles by LDL receptors in the liver. Consequently, FH patients have a high risk of cardiovascular disease (CVD). However, among these patients, there is marked variance in age of onset of CVD and a proportion of untreated patients do not develop CVD at all. Statin treatment can greatly reduce risk, and since it is not yet possible to precisely predict which FH patients will develop CVD, all patients initiate treatment once the diagnosis has been made. The purpose of this article is to provide an update of clinical and genetic risk factors influencing CVD risk in FH patients, and to discuss future lines of research that could uncover improved methods of treatment for heterozygous FH patients.",

author = "Oosterveer, {Dani{\"e}lla M.} and Jorie Versmissen and Schinkel, {Arend F.L.} and Langendonk, {Janneke G.} and Monique Mulder and Sijbrands, {Eric J.G.}",

year = "2010",

month = apr,

doi = "10.2217/clp.10.9",

language = "English",

volume = "5",

pages = "189--197",

journal = "Future Lipidology",

issn = "1758-4299",

publisher = "Taylor & Francis Ltd",

number = "2",

}

TY - JOUR

T1 - Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia

AU - Oosterveer, Daniëlla M.

AU - Versmissen, Jorie

AU - Schinkel, Arend F.L.

AU - Langendonk, Janneke G.

AU - Mulder, Monique

AU - Sijbrands, Eric J.G.

PY - 2010/4

Y1 - 2010/4

N2 - Patients with familial hypercholesterolemia (FH) have high levels of LDL-C, owing to defective uptake of these particles by LDL receptors in the liver. Consequently, FH patients have a high risk of cardiovascular disease (CVD). However, among these patients, there is marked variance in age of onset of CVD and a proportion of untreated patients do not develop CVD at all. Statin treatment can greatly reduce risk, and since it is not yet possible to precisely predict which FH patients will develop CVD, all patients initiate treatment once the diagnosis has been made. The purpose of this article is to provide an update of clinical and genetic risk factors influencing CVD risk in FH patients, and to discuss future lines of research that could uncover improved methods of treatment for heterozygous FH patients.

AB - Patients with familial hypercholesterolemia (FH) have high levels of LDL-C, owing to defective uptake of these particles by LDL receptors in the liver. Consequently, FH patients have a high risk of cardiovascular disease (CVD). However, among these patients, there is marked variance in age of onset of CVD and a proportion of untreated patients do not develop CVD at all. Statin treatment can greatly reduce risk, and since it is not yet possible to precisely predict which FH patients will develop CVD, all patients initiate treatment once the diagnosis has been made. The purpose of this article is to provide an update of clinical and genetic risk factors influencing CVD risk in FH patients, and to discuss future lines of research that could uncover improved methods of treatment for heterozygous FH patients.

UR - http://www.scopus.com/inward/record.url?scp=77950217259&partnerID=8YFLogxK

U2 - 10.2217/clp.10.9

DO - 10.2217/clp.10.9

M3 - Review article

AN - SCOPUS:77950217259

VL - 5

SP - 189

EP - 197

JO - Future Lipidology

JF - Future Lipidology

SN - 1758-4299

IS - 2

ER -

Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this